

ChemoCentryx Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 12-Dec-2012

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Product Portfolio Summary..... 8

Product Portfolio Drugs..... 13

[Return to Table of Contents](#)

ChemoCentryx Inc

COMPANY OVERVIEW

| | |
|---------------------------------------|--|
| Company Name | ChemoCentryx Inc |
| Parent Company Name | ChemoCentryx Inc |
| Website | http://www.chemocentryx.com/ |
| Country | US |
| Number of Drugs in Active Development | 9 |
| Number of Inactive Drugs | 12 |
| Number of Patents as Owner | 53 |
| Number of Patents as Third Party | 0 |
| Number of Deals | 4 |
| Key Indications | Autoimmune disease, Inflammatory disease, Rheumatoid arthritis, Inflammatory bowel disease, Restenosis, Multiple sclerosis, Cancer, Vasculitis, Atopic dermatitis, Metabolic disorder, Non-insulin dependent diabetes |
| Key Target-based Actions | CCR1 chemokine antagonist, CCR2 chemokine antagonist, CCR9 chemokine antagonist, CXCR7 chemokine antagonist, Complement C5a receptor antagonist, Chemokine receptor-like 1 antagonist, CCR4 chemokine antagonist, CD11b antagonist, CXCR3 chemokine antagonist, CXCR4 chemokine antagonist, CXCR6 chemokine antagonist |
| Key Technologies | Small molecule therapeutic, Oral formulation, Capsule formulation, Analytical method, Antibody, Diagnostic method, Drug screening, Fluorescence, Imaging, Immunodetection, Monoclonal antibody |

COMPANY PROFILE

SUMMARY

ChemoCentryx is a private technology and drug discovery company located in the US, and is committed to the R&D of orally-delivered small molecule therapeutics for infectious and inflammatory diseases based on the biology of chemokines and chemokine receptors.

Initial funding for the company was provided through a Research, Collaborative and Investment Agreement with Techne Corp and their subsidiary, R&D Systems. Major non-dilutive support has also been obtained through the Defense Advanced Research Program through two separate grants.

LICENSING AGREEMENTS

In August 2006, GlaxoSmithKline (GSK) and ChemoCentryx joined forces to develop drugs targeting chemokine and chemoattractant receptors for the treatment of inflammatory disorders. The deal included CCX-282, for which ChemoCentryx retained an option to codevelop and comarket to US specialists. ChemoCentryx would receive \$63.5 million in cash and series D financing upfront, research funding, up to \$1.5 billion in milestone payments and double-digit royalties.

EARLY R&D

By April 2008, the company was evaluating compounds targeting chemokine receptors such as CCR5, CCR10, CCR12 and CXCR2 for preclinical development.

FINANCIAL

In February 2012, the company priced an IPO of 4.5 million shares at \$10.00 per share, and underwriters were granted a 30-day option to purchase an additional 0.675 million shares, to cover overallocments. The shares would begin trading on the NASDAQ Global Market under 'CCXI' symbol from February 08, 2012. At that time, the offering was expected to close on February 13, 2012; the offering was completed later in February 2012; at that time, the company raised \$63.7 million gross proceeds from the private placement. Net proceeds raised were \$57 million.

[Return to Table of Contents](#)



In June 2006, ChemoCentryx completed a series C financing, raising \$17.7 million.

In June 2004, ChemoCentryx announced that it had closed a private financing round raising gross proceeds of \$33 million. HBM BioVentures and Alta Partners acted as significant new investors in the round.

R&D GRANTS

In October 2003, the NIAID awarded ChemoCentryx a \$14 million grant to develop first-in-class immune modulatory agents targeting chemokine receptors, for the prevention and treatment of infectious diseases that may be caused by biological warfare pathogens.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



Drugs by Indication Table


| Indication | Active | Inactive | Total |
|----------------------|--------|----------|-------|
| Inflammatory disease | 6 | 7 | 13 |

[Return to Table of Contents](#)

| | | | |
|--------------------------|---|---|----|
| Immune disorder | 6 | 6 | 12 |
| Gastrointestinal disease | 2 | 3 | 5 |
| Neoplasm | 1 | 3 | 4 |
| Dermatological disease | 1 | 2 | 3 |
| Neurological disease | 1 | 2 | 3 |
| Metabolic disorder | 2 | 1 | 3 |
| Cardiovascular disease | 2 | 1 | 3 |
| Musculoskeletal disease | 1 | 1 | 2 |
| Infectious disease | 0 | 1 | 1 |
| Respiratory disease | 1 | 0 | 1 |
| Hematological disease | 0 | 1 | 1 |
| Endocrine disease | 1 | 0 | 1 |
| Genitourinary disease | 1 | 0 | 1 |

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status | Number of Drugs |
|--------------------|-----------------|
| Phase 2 Clinical | 3 |

[Return to Table of Contents](#)

| | |
|-------------------------|---|
| Phase 1 Clinical | 1 |
| Discovery | 5 |
| Discontinued | 2 |
| No Development Reported | 9 |

DEALS

| Deal Type | Principal | | Partner | | Total |
|--|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Drug - Early Research/Development | 0 | 0 | 1 | 0 | 1 |
| Drug - Development/Commercialization License | 1 | 0 | 0 | 0 | 2 |
| Drug - Commercialization License | 1 | 0 | 0 | 0 | 1 |

CLINICAL TRIALS

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|--------------------------|---------|-----|
| Inflammatory disease | 1 | 13 |
| Immune disorder | 0 | 10 |
| Gastrointestinal disease | 1 | 9 |
| Metabolic disorder | 1 | 4 |
| Endocrine disease | 1 | 3 |
| Musculoskeletal disease | 0 | 3 |
| Cardiovascular disease | 1 | 3 |
| Neurological disease | 0 | 2 |
| Genitourinary disease | 2 | 2 |

Trials by Phase

| Phase | Ongoing | All |
|---------|---------|-----|
| Phase 3 | 0 | 1 |
| Phase 2 | 3 | 8 |
| Phase 1 | 0 | 8 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

[Return to Table of Contents](#)



Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

| Indication | As Owner | As Third Party | Total |
|--------------------------------|----------|----------------|-------|
| Immune disorder | 37 | 0 | 37 |
| Neoplasm | 30 | 0 | 30 |
| Ocular disease | 3 | 0 | 3 |
| Metabolic disorder | 14 | 0 | 14 |
| Neurological disease | 24 | 0 | 24 |
| Prophylaxis | 2 | 0 | 2 |
| Degeneration | 8 | 0 | 8 |
| Andrology | 1 | 0 | 1 |
| Cardiovascular disease | 24 | 0 | 24 |
| Endocrine disease | 12 | 0 | 12 |
| Genitourinary disease | 4 | 0 | 4 |
| Dermatological disease | 23 | 0 | 23 |
| Otorhinolaryngological disease | 1 | 0 | 1 |
| Gastrointestinal disease | 22 | 0 | 22 |
| Hematological disease | 7 | 0 | 7 |
| Musculoskeletal disease | 29 | 0 | 29 |
| Nutritional disorder | 5 | 0 | 5 |
| Respiratory disease | 23 | 0 | 23 |
| Infectious disease | 24 | 0 | 24 |
| Injury | 2 | 0 | 2 |
| Inflammatory disease | 44 | 0 | 44 |
| Gynecology and obstetrics | 2 | 0 | 2 |

[Return to Table of Contents](#)



* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

CCX-168

| | |
|-----------------------------|--|
| Drug Name | CCX-168 |
| Key Synonyms | |
| Originator Company | ChemoCentryx Inc |
| Active Companies | GlaxoSmithKline plc, ChemoCentryx Inc |
| Inactive Companies | |
| Highest Status | Phase 2 Clinical |
| Active Indications | Autoimmune disease, Inflammatory disease, Vasculitis |
| Target-based Actions | Complement C5a receptor antagonist, CD11b antagonist |
| Other Actions | Anti-inflammatory |
| Technologies | Oral formulation, Small molecule therapeutic |
| Last Change Date | 15-Jun-2012 |

CCX-140

| | |
|-----------------------------|---|
| Drug Name | CCX-140 |
| Key Synonyms | |
| Originator Company | ChemoCentryx Inc |
| Active Companies | ChemoCentryx Inc |
| Inactive Companies | |
| Highest Status | Phase 2 Clinical |
| Active Indications | Diabetic nephropathy, Multiple sclerosis, Restenosis, Non-insulin dependent diabetes, End stage renal disease |
| Target-based Actions | CCR2 chemokine antagonist |
| Other Actions | Anti-inflammatory, Hypoglycemic agent |
| Technologies | Oral formulation, Capsule formulation, Small molecule therapeutic |
| Last Change Date | 28-Nov-2012 |

[Return to Table of Contents](#)

CCX-354

| | |
|-----------------------------|---|
| Drug Name | CCX-354 |
| Key Synonyms | |
| Originator Company | ChemoCentryx Inc |
| Active Companies | GlaxoSmithKline plc, ChemoCentryx Inc |
| Inactive Companies | Forest Laboratories Inc |
| Highest Status | Phase 2 Clinical |
| Active Indications | Rheumatoid arthritis |
| Target-based Actions | CCR1 chemokine antagonist |
| Other Actions | Anti-inflammatory, Leukocyte infiltration inhibitor |
| Technologies | Oral formulation, Small molecule therapeutic |
| Last Change Date | 14-Jun-2012 |

CCX-872

| | |
|-----------------------------|--|
| Drug Name | CCX-872 |
| Key Synonyms | |
| Originator Company | ChemoCentryx Inc |
| Active Companies | ChemoCentryx Inc |
| Inactive Companies | |
| Highest Status | Phase 1 Clinical |
| Active Indications | Metabolic disorder |
| Target-based Actions | CCR2 chemokine antagonist |
| Other Actions | |
| Technologies | Oral formulation, Small molecule therapeutic |
| Last Change Date | 28-Nov-2012 |

[Return to Table of Contents](#)

CCR4 antagonist (oral, pulmonary diseases/atopic dermatitis/autoimmune disease), ChemoCentryx

| | |
|-----------------------------|---|
| Drug Name | CCR4 antagonist (oral, pulmonary diseases/atopic dermatitis/autoimmune disease), ChemoCentryx |
| Key Synonyms | |
| Originator Company | ChemoCentryx Inc |
| Active Companies | ChemoCentryx Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Autoimmune disease, Lung disease, Atopic dermatitis |
| Target-based Actions | CCR4 chemokine antagonist |
| Other Actions | Dermatological agent, Anti-inflammatory |
| Technologies | Oral formulation, Small molecule therapeutic |
| Last Change Date | 13-Sep-2012 |

CXCR6 antagonist (oral, inflammatory/autoimmune diseases), ChemoCentryx

| | |
|-----------------------------|---|
| Drug Name | CXCR6 antagonist (oral, inflammatory/autoimmune diseases), ChemoCentryx |
| Key Synonyms | |
| Originator Company | ChemoCentryx Inc |
| Active Companies | ChemoCentryx Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Autoimmune disease, Inflammatory disease |
| Target-based Actions | CXCR6 chemokine antagonist |
| Other Actions | Anti-inflammatory |
| Technologies | Oral formulation, Small molecule therapeutic |
| Last Change Date | 13-Sep-2012 |

[Return to Table of Contents](#)

CCX-507

| | |
|----------------------|----------------------------|
| Drug Name | CCX-507 |
| Key Synonyms | |
| Originator Company | ChemoCentryx Inc |
| Active Companies | ChemoCentryx Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Inflammatory bowel disease |
| Target-based Actions | CCR9 chemokine antagonist |
| Other Actions | Anti-inflammatory |
| Technologies | Small molecule therapeutic |
| Last Change Date | 28-May-2012 |

CCR1 antagonists (autoimmune diseases), ChemoCentryx

| | |
|----------------------|--|
| Drug Name | CCR1 antagonists (autoimmune diseases), ChemoCentryx |
| Key Synonyms | |
| Originator Company | ChemoCentryx Inc |
| Active Companies | ChemoCentryx Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Autoimmune disease |
| Target-based Actions | CCR1 chemokine antagonist |
| Other Actions | Chemotaxis inhibitor |
| Technologies | Small molecule therapeutic |
| Last Change Date | 04-Jun-2012 |

[Return to Table of Contents](#)

CXCR7 antagonists, ChemoCentryx

| | |
|-----------------------------|---|
| Drug Name | CXCR7 antagonists, ChemoCentryx |
| Key Synonyms | |
| Originator Company | ChemoCentryx Inc |
| Active Companies | ChemoCentryx Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Inflammatory disease, Cancer, Glioblastoma |
| Target-based Actions | CXCR7 chemokine antagonist |
| Other Actions | Anticancer, Anti-inflammatory, Angiogenesis inhibitor |
| Technologies | Oral formulation, Small molecule therapeutic |
| Last Change Date | 12-Sep-2012 |

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

